Johnson & Johnson MedTech Acquires Laminar, Inc.

Johnson & Johnson Acquires Atraverse Medical

May 28, 2026

Medical Devices

Johnson & Johnson acquired Atraverse Medical, strengthening its J&J MedTech cardiac electrophysiology portfolio. The acquisition follows the May 15, 2026 close and is referenced in connection with medtech founder John Slump’s subsequent launch of Metis MedTech.

Johnson & Johnson to Acquire Atraverse Medical

April 26, 2026

Medical Devices

Johnson & Johnson entered into a definitive agreement to acquire Atraverse Medical, a privately held medtech company developing the HOTWIRE Transseptal Access System for left-heart access during cardiac electrophysiology procedures. The deal is expected to close in Q2 2026, subject to customary closing conditions, with financial terms not disclosed.

Laborie Acquires the JADA® System from Organon

January 28, 2026

Medical Devices

Laborie Medical Technologies has completed the acquisition of the JADA® System and the team behind it from Organon in a transaction announced in late January 2026. The deal — part of Organon’s divestiture program (previously disclosed as up to $465 million) — brings more than 90 employees and an FDA-cleared device for rapid control of postpartum hemorrhage into Laborie’s obstetrics portfolio to expand the company’s maternal health capabilities.

W. L. Gore & Associates to Acquire Conformal Medical

January 6, 2026

Medical Devices

W. L. Gore & Associates entered into a definitive agreement to acquire Conformal Medical, a medical device company developing the investigational CLAAS AcuFORM System for left atrial appendage occlusion (LAAO) aimed at stroke prevention in non-valvular atrial fibrillation. The deal is expected to close in early 2026, subject to regulatory approval, and is intended to add the CLAAS AcuFORM technology to Gore’s endovascular cardiac portfolio.

Aileron Therapeutics Acquires Lung Therapeutics

October 31, 2023

Biotechnology

Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.

Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022

Medical Devices

Johnson & Johnson completed its acquisition of Abiomed through a tender offer and subsequent merger, for an upfront payment of $380.00 per share in cash (enterprise value ~ $16.6 billion), plus a non-tradeable contingent value right (CVR) up to $35.00 per share based on milestones. Abiomed will operate as a standalone business within Johnson & Johnson’s MedTech segment.